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Abstract 
Altered DNA methylation is associated with important and common pathologies such as 
cancer. The origin of altered DNA methylation is unknown. The methyl groups for DNA 
methylation are provided by methionine metabolism. This metabolism is characterized by a 
high inter-individual variability, which is in part explained by genetic variants. In a cohort of 
313 individuals derived from a family-based study with index cases of cerebrovascular 
disease we analysed whether global methylation of leukocyte DNA was associated with age, 
gender, homocysteine plasma levels or functionally relevant genetic variants. We observed an 
association of the G-allele of the methionine synthase variant c.2756A>G (D919G) with 
global methylation (% methylation ± 1 standard deviation, AA: 41.3±14.9; AG: 36.4±18.2; 
GG: 30.8±16.9; F=4.799; p=0.009). The methionine synthase variant c.2756A>G is 
associated with various types of cancer. Our data suggest that an impact on DNA methylation 
may contribute to the clinical relevance of the methionine synthase variant.    
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Introduction 
DNA methylation is a well-known epigenetic mechanism and associated with important and 
common pathologies such as cancer [1]. The origin of altered DNA methylation, however, 
remains unclear. Recently, a variety of inactivating mutations in genes controlling the 
epigenome have been described in whole genome sequencing of human cancers [2,3]. These 
mutations have the potential to disrupt DNA methylation patterns and therefore contribute to 
disease development as much as epigenetic silencing is able to cause the loss of function of 
genes and predisposes to genetic mutations, leading to an interplay between genetic mutations 
and epigenetic alterations . Several human cancers show mutations of epigenetic modifiers 
that presumably lead to altered DNA methylation. In acute myeloic leukemia DNA 
methyltransferase 3a (DNMT3A) mutations have been found to be associated with differences 
in global DNA methylation patterns [4], in colorectal cancer mutational inaction of DNMT1 
was described [5], and isocitrate dehydrogenase 1/2 (IDH 1/2) mutated gliomas show distinct 
epigenetic profiles, characterized by a high frequency of methylated CpG islands [6].  
The human methionine metabolism is closely linked to DNA synthesis and epigenetics 
(Figure 1). Methionine is activated to S‑adenosyl-methionine (SAM), which is the only and 
ubiquitous methyl donor for DNA methylation mediated by the DNA methyltransferases.  
Methionine metabolism is known to be influenced by several factors including genetic 
variants and nutrition. Some genetic variants of methionine metabolism have been reported to 
be associated with vascular disease, neurodegeneration or cancer [7]. It is therefore plausible 
to assume that some genetic variants of the methione metabolism could influence DNA 
methylation. This study investigated whether genetic variations of methionine metabolism 
influence the global DNA methylation in sample of individuals of whom several genetic 
variations of methionine metabolism were already known [8].  
 
Materials and Methods 
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For this study we used a gDNA library consisting of 313 gDNA samples of German 
individuals of white Caucasian ancestry from an ongoing study investigating the inheritance 
of the wall thickness of the common carotid intima media thickness [8,9]. Of the 313 
individuals, n= 85 were patients with vascular disease (mean age in years ± 1 standard 
deviation: 63.4±8.9; 22% female), n= 68 were spouses (62.0±8.7 years; 79% female), and n= 
160 were offspring (35.0±7.9years, 51% female) of these patients and spouses. All patients 
with clinical or laboratory signs of inflammation, including changes in complete blood count 
(CBC) and increases of C-reactive protein (CRP), were excluded from the study. All patients 
with laboratory signs of decreased kidney function were excluded from the study. Individuals 
were of Caucasian origin and lived in the area of Bonn, Germany. The patients with vascular 
disease were defined by an increase of the intima-media thickness of the common carotid 
artery [9]. Spouses and offspring had no increase of the intima-media thickness and no history 
of vascular events. For these 313 individuals, genotypes were known for the following genetic 
variants of methionine metabolism, i.e.  CBS c.844_855ins68 (change of transcript levels, 
Genbank Number S78267.1)[10], DHFR c.594+59del19bp (change of transcript levels, 
rs70991108)[11], MTHFR c.677C>T (A222V, rs1801133) [12] and c.1298A>C (E429A, 
rs1801131) [13], MTR c.2756A>G (D919G, rs1805087) [14], and reduced folate carrier 1 
(RFC1) c.80G>A (R27H, rs1051266) [8,9,15]; Figure 1.  
Plasma homocysteine levels were determined by fully automated particle-enhanced 
immunonephelometry with a BN II System (Dade Behring).  
 
 
Measurement of DNA methylation 
 
Total DNA was extracted from frozen EDTA-blood using QIAmp DNA Blood Mini Kit 
(Qiagen, Hilden, Germany). Global methylation status was measured as previously described 
[16]. Briefly, 0.5-1 µg of genomic DNA is digested overnight with a 10-fold excess of HpaII 
or MspI end nuclease according to manufacturer’s protocol (New England Biolabs, Beverly, 
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MA). MspI cuts independently from methylation status at 5’-CCGG-3’, while cutting of 
HpaII depends on the DNA-methylation status. The single nucleotide extension reaction is 
performed in a 25 µl reaction mixture containing 2 Units of polymerase (Genecraft: 
Supratherm, Lüdinghausen, Germay), polymerase-buffer (Genecraft) and 0.4 mM Cy5-
labelled dCTP (GE Healthcare Europe, Munich, Germany), and incubated at 56° for 1 h on an 
I-Cycler (Biorad, Hercules, CA) to allow filling of overlapping ends with dCTPs, then placed 
on ice. Free dCTPs are separated by QIAquick Nucleotide removal kit (Qiagen) and 
fluorescently labelled DNA is eluted by 100µl of H2O. Fluorescence is measured on a 
Molecular Imager FX (Biorad) and quotients of 1-(HpaII/MspI) are calculated from 3 
independent experiments [16]. 
 
Statistical analysis 
The Kolmogorov-Smirnov Test revealed normal distribution of all data analysed. Deviation 
from Hardy-Weinberg-Equilibrium was tested for all genotypes studied using the online tool 
of the Institute for Human Genetics, Munich, accessible at http://ihg.gsf.de/cgi-
bin/hw/hwa1.pl. Mixed linear models (using the restricted estimated maximum likelihood 
method) were performed to evaluate the impact of the analysed genotypes on global DNA 
methylation. Akaike’s information criterion (AIC) was used to assess the best fitting model. 
To cope with the family structure within our sample, we computed families as repeated 
measurements applying a scaled identity covariance structure. Linear regression analysis was 
used to test associations between the covariates homocysteine, age, smoking, and all tested 
genotypes and global DNA methylation as dependent variable. Comparison of the global 
DNA methylation in different genotypes of the same genetic variant was made using one-way 
analysis of variance (ANOVA).   
P-values of less than 0.05 (two-tailed) were considered to indicate statistical significance. 
Data were analyzed employing the statistical package for the social sciences (SPSSTM for 
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Windows 14.0; SPSS Inc., Chicago, IL).   
 
Results 
Linear regression analysis revealed no significant influence of age (B=-0.42; P=0.469) and 
homocysteine (B=0.194; P=0.392) on global DNA methylation. Neither did gender (t-Test: 
T=0.007; df=311; P=0.995) nor smoking status (T=0.302; df=296; P=0.763).  
All genotypes studied did not show deviation from Hardy-Weinberg-Equilibrium with the 
exception of DHFR19. Interestingly, this deviation was only driven by the offspring group in 
the study population. As we did not observe significant differences in genotype distribution 
between the three groups (cases, offspring, spouses), we decided to include DHFR into the 
subsequent analyses. Table 2 provides the investigated genotypes and their association with 
global DNA methylation. F and P-values were derived from the parameter estimates and 
corrected for multiple testing using Bonferroni’s procedure. We analyzed whether the 
proportion of variance of DNA methylation derived by the single genotypes was significant. 
As shown in Table 2, the MTR c.2756A>G genotype was associated with global DNA 
methylation showing an allele-dosage effect with a higher methylation associated with the 
wild-type A-allele. This association was only significant for the total sample size, but not, if 
patients, spouses and offspring were analysed separately. We did not observe any further 
significant results for all other investigated genotypes (Table 2). We tested our model in a 
general linear analysis and observed that the MTR c.2756A>G genotype (p=0.048; 50.88% of 
variance), but not age, sex, family status or any interaction between factors and covariates was 
associated with global DNA methylation. Homocysteine plasma levels were not associated 
with MTR alleles (ANOVA: F=0.87; p=0.419). Homocysteine plasma levels did not correlate 
with methylation (Pearson’s correlation: -0.033; p=0.555). 
 
Discussion 
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This study shows that the G-allele of MTR c.2756A>G (D919G) is associated with reduced 
global DNA-methylation.  
The genotype frequencies of the current study are within the range reported in other study 
populations for CBS c.844_855ins68[10,17], DHFR c.594+59del19bp [11,18], MTHFR 
c.677C>T [12,19] and c.1298A>C [13,20], RFC1 c.80G>A [15], and MTR c.2756A>G [14,21]. 
This shows that all genotype frequencies reported in the current study are representative and 
are not due to the current study population or patient selection. 
 
The mechanism how MTR c.2756A>G leads to reduced global DNA-methylation remains 
speculative as the biological effect of MTR c.2756A>G is unclear. In vitro analyses of the 
variant enzyme activity are lacking, and associations of the different alleles with 
homocysteine plasma levels are controverse [22,23]. Paz et al. found that in tumors occurring 
in individuals who carried 2756GG showed a lower frequency of CpG island 
hypermethylation in tumor suppressor genes [24]. In the population of our study we did not 
detect an association between the MTR genotype and homocysteine plasma levels or between 
homocysteine levels and DNA methylation. This suggests that the MTR variant might have an 
effect on DNA methylation independent from effects on homocysteine levels, alternatively 
homocysteine levels might additionally be controlled by altered flux through the 
transsulfuration or the alternative remethylation pathway based on the enzyme betaine-
homocysteine methyltransferase [25].  
 
The G-allele of MTR c.2756A>G has already been reported to decrease the susceptibility to 
various cancers [26-31]. The observed effect of the G-allele of the MTR c.2756A>G variant 
on DNA methylation suggests that the protective effect of this variant on several types of 
cancer may be mediated decreased CpG island methylation, because hypermethylation of 
DNA repair and tumor suppressor genes can result in the inactivation of these genes resulting 
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in increased levels of genetic damage, predisposing cells to later genetic instability which then 
contributes to tumor progression [32]. For example, the tumour suppressor genes Von 
Hippel–Lindau (VHL) in renal cancer and CDKN2A in several tumour types are DNA 
hypermethylated [33,34]. This may also explain why the G-allele of MTR c.2756A>G has 
been described to be associated with longevity [35]. 
A recent paper of Weiner et al, described that the homozygous genotype of MTR c.2756GG is 
associated with increased global DNA methylation when compared to homozygous carriers of 
the MTRc.2756AA wildtype in their study population of healthy Caucasian Russian blood 
donors. In addition to that they showed a significant decrease of global DNA methylation in 
homozygous MTHFR c.677TT carries in comparison to probands with the MTHFR c.677CC 
genotype [36]. The difference between this study and the current data might be explained by 
differences in populations and other factors influencing DNA methylation such as folate 
levels, alcohol consumption, and smoking [37,38]. 
Finally, it is tempting to speculate about possible clinical implications of the data presented. 
MTR activity depends on folate and vitamin B12 [25], which might provide a link of 
nutritional factors, epigenetics and cancer development [39]. Additional studies on the 
functional consequences of the MTR c.2756A>G polymorphism and of folate and vitamin 
B12 on the DNA methylation patterns are warranted. 
Our results are limited due to different factors: First, we did not analyze a population based 
cohort, but families with at least one person suffering from vascular disease. However, in all 
subgroups defined by family status, results tended in the same direction making it unlikely 
that the overall effect is driven by a specific effect in vascular patients only. Second, we did 
not investigate genetically independent subjects, but family members. We tried to control for 
this influence in the mixed models by treating family members as linked samples and 
modeling the covariance structure accordingly. Further, the power of the study might not have 
been sufficient to detect small effects of genotypes on DNA methylation. In a study of 384 
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healthy Japanese women, the amount of dietary folate intake, but not MTR c.2756A>G, was 
associated with global methylation of leukocyte levels [40]. Methionine metabolism is 
strongly influenced by folate and vitamin B12 intake and blood levels, and such parameters 
were not measured in our study. Thus, we cannot decide whether differences in these 
parameters might have contributed to the discrepancy of the results between the Japanese and 
our study population.  
 
 
 
Future perspective 
Global DNA methylation is an important epigenetic mechanism and associated with clinically 
important diseases such as cancer. This study shows that the G-allele of MTR c.2756A>G 
(D919G) is associated with reduced global DNA-methylation.  Future studies have to describe 
the further mechanisms leading to altered DNA methylation including other genetic 
variations, but also environmental influences like nutrition or medications. Probably there is a 
complex interplay between all factors leading to altered DNA methylation and precise 
characterization of the study population is essential to achieve meaningful results. 
 
Executive Summary 
 The origin of altered DNA methylation is unknown.  
 In a cohort of 313 individuals we observed an association of the G-allele of the 
methionine synthase variant c.2756A>G (D919G) with global methylation. 
 Our data suggest that an impact on DNA methylation may contribute to the clinical 
relevance of the methionine synthase variant.    
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Table 1. Polymorphisms and global leukocyte CpG island methylation  
Variant 
rs number/Genbank No. 
genotype 
number of individuals (%) 
global DNA methylation 
ANOVA HWE 
(Pearson’s) 
      
 
CBS c.844_855ins68 
S78267.1 
del/del:  
274 (87.5%) 
39.3±16.2 
del/ins:  
38 (12.1%) 
37.2±18.8 
ins/ins:  
1 (0.3%) 
34.4 
 
F=1.237 
p=0.292 
 
F=-0.015 
p=0.83 
      
 
DHFR c.594+59del19bp 
NM_000791.3 
del/del: 
70 (22.4%) 
40.0±16.0 
del/ins: 
134 (42.8%) 
38.9±16.7 
ins/ins: 
109 (34.8%) 
38.0±16.9 
 
F=0.313 
p=0.732 
 
F=0.13 
p=0.02
#
 
      
 
MTHFR c.677C>T 
rs1801133 
CC: 
151 (48.2%) 
38.6±15.9 
CT: 
139 (44.4%) 
39.6±17.4 
TT: 
23 (7.3%) 
36.3±16.0 
 
F=0.396 
p=0.673 
 
F=-0.062 
p=0.27 
      
 
MTHFR c.1298A>C 
rs1801131 
AA: 
151 (48.2%) 
39.4±16.1 
AC: 
136 (43.4%) 
38.8±17.5 
CC: 
26 (8.3%) 
36.1±14.4 
 
F=0.742 
p=0.477 
 
F=-0.029 
p=0.60 
      
 
RFC1 c.80G>A 
rs1051266 
GG: 
102 (32.6%) 
40.6±19.1 
AG: 
149 (47.6%) 
39.7±16.1 
AA: 
62 (19.8%) 
36.6±15.4 
 
F=1.534 
p=0.217 
 
F=0.037 
p=0.51 
      
 
MTR c.2756A>G 
rs1805087 
AA: 
184 (58.8%) 
41.3±14.9 
AG: 
112 (35.8%) 
36.4±18.2 
GG: 
17 (5.4%) 
30.8±16.9 
 
F=4.799 
p=0.009* 
 
F=-0.012 
p=0.83 
 
MTR c.2756A>G 
Patients only 
AA: 
50 (58.8%) 
33.5±21.3 
AG: 
30 (35.3%) 
32.9±24.0 
GG: 
5 (5.9%) 
16.1±38.9 
 
F=1.279 
p=0.284 
 
F=-0.012 
p=0.91 
 
MTR c.2756A>G 
Spouses only  
AA: 
42 (61.8%) 
38.3±19.9 
AG: 
22 (32.4%) 
34.6±21.8 
GG: 
4 (5.9%) 
27.0±21.5 
 
F=1.599 
p=0.205 
 
F=0.059 
p=0.63 
 
MTR c.2756A>G 
Offspring only  
AA: 
92 (57.5%) 
38.3±19.9 
AG: 
60 (37.5%) 
34.6±21.8 
GG: 
8 (5.0%) 
27.0±21.5 
 
F=1.599 
p=0.205 
 
F=-0.047 
p=0.60 
 
 
Table 1: All tested genetic variants of the methionine metabolism and their association with 
global DNA methylation. The MTR variant c.2756A>G (allele-dosage effect with the 
wildtype A-allele) was significantly associated with global DNA methylation (*). CBS 
(cystathionine beta-synthase), DHFR (dihydrofolate reductase), MTHFR (5,10-
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methylenetetrahydrofolate reductase), MTR (5-methyltetrahydrofolate-homocysteine S-
methyltransferase), RFC (reduced folate carrier). 
 
 
Figure 1. Methionine-homocysteine metabolism  
 
 
Figure 1: In human methionine metabolism methionine becomes activated to S-
adenosylmethionine (SAM) via methionine adenosyltransferase (MAT). SAM is an 
ubiquitious methyl group donor, e.g., for the synthesis of biogenic amines and DNA 
methylation. Degradation product of SAM is S-adenosylhomocysteine (SAH), which is 
hydrolyzed to homocysteine per homocysteine hydrolase (SAHH). Hcys can either be 
transsulfurated to cystathionine and cysteine via vitamin B6-dependent cystathionine beta-
synthase (CBS) and cystathionine gamma lyase (CGL), or alternatively, homocysteine can be 
remethylated to methionine. This is done by 5-methyltetrahydrofolate-homocysteine S-
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methyltransferase (MTR, also called methionine synthase), which needs a derivate of vitamin 
B12 (methylcobalamin) as well as a derivate of folate (5-methyltetrahydrofolate; 5-MTHF) as 
cofactors. Vitamin B12 is transported by transcobalamin 2 (Tc2), and 5-
methyltetrahydrofolate is synthesized by 5,10-methylenetetrahydrofolate reductase (MTHFR) 
from 5,10-methylenetetrahydrofolate (5,10-MTHF), which is synthesized from folate by 
dihydrofolate reductase (DHFR) in two subsequent steps.  
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Figure 2. Impact of MTR c.2756A>G on global DNA methylation 
 
 
Figure 2: MTR c.2756 A>G genotypes and global DNA methylation. P values given are 
derived from the all pairwise comparison of the estimated marginal means and are corrected 
according to Bonferroni. 
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